These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 38610980)

  • 1. An Updated Review of Management of Resectable Stage III NSCLC in the Era of Neoadjuvant Immunotherapy.
    Verma S; Breadner D; Mittal A; Palma DA; Nayak R; Raphael J; Vincent M
    Cancers (Basel); 2024 Mar; 16(7):. PubMed ID: 38610980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant and Adjuvant Immunotherapy in Early-Stage Non-Small Cell Lung Cancer.
    Shukla N; Hanna N
    Lung Cancer (Auckl); 2021; 12():51-60. PubMed ID: 34234606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of Resectable Stage III-N2 Non-Small-Cell Lung Cancer (NSCLC) in the Age of Immunotherapy.
    Mielgo-Rubio X; Montemuiño S; Jiménez U; Luna J; Cardeña A; Mezquita L; Martín M; Couñago F
    Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant immune checkpoint inhibitors in resectable non-small-cell lung cancer: a systematic review.
    Ulas EB; Dickhoff C; Schneiders FL; Senan S; Bahce I
    ESMO Open; 2021 Oct; 6(5):100244. PubMed ID: 34479033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant and neo-adjuvant immunotherapy in resectable non-small cell lung cancer (NSCLC): Current status and perspectives.
    Xu Z; Zou Z; Hao X; Xing P; Li J
    Cancer Innov; 2023 Feb; 2(1):65-78. PubMed ID: 38090369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Emerging Role of Immunotherapy in Resectable Non-Small Cell Lung Cancer.
    Dunne EG; Fick CN; Isbell JM; Chaft JE; Altorki N; Park BJ; Spicer J; Forde PM; Gomez D; Iyengar P; Harpole DH; Stinchcombe TE; Liberman M; Bott MJ; Adusumilli PS; Huang J; Rocco G; Jones DR
    Ann Thorac Surg; 2024 Jul; 118(1):119-129. PubMed ID: 38316378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current status and future perspectives on immunotherapy in neoadjuvant therapy of resectable non-small cell lung cancer.
    Liu X; Xing H; Liu H; Chen J
    Asia Pac J Clin Oncol; 2022 Aug; 18(4):335-343. PubMed ID: 34811893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy in Early-Stage Non-Small Cell Lung Cancer (NSCLC): Current Evidence and Perspectives.
    Lazzari C; Spagnolo CC; Ciappina G; Di Pietro M; Squeri A; Passalacqua MI; Marchesi S; Gregorc V; Santarpia M
    Curr Oncol; 2023 Mar; 30(4):3684-3696. PubMed ID: 37185393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surgical Perspective on Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer.
    Lee JM; Tsuboi M; Brunelli A
    Ann Thorac Surg; 2022 Oct; 114(4):1505-1515. PubMed ID: 34339672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial.
    Sun C; Liu Y; Zhang P; Wang X; Xu Y; Lin X; Ma X; Guo Y; Qiu S; Shao G; Yang Z; Ma K
    J Cancer Res Clin Oncol; 2023 Feb; 149(2):819-831. PubMed ID: 35192053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The emerging perioperative treatment paradigm for non-small cell lung cancer: a narrative review.
    Christopoulos P
    Chin Clin Oncol; 2024 Feb; 13(1):12. PubMed ID: 38372058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy in potentially resectable stage IIIA/IIIB non-small cell lung cancer: Neo-Pre-IC, a single-arm phase 2 trial.
    Sun C; Wang X; Xu Y; Shao G; Chen X; Liu Y; Zhang P; Lin X; Ma X; Qiu S; He H; Yang Z; Ma K
    EClinicalMedicine; 2024 Feb; 68():102422. PubMed ID: 38304743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of Neoadjuvant Immune Checkpoint Inhibitors in Resectable Non-Small Cell Lung Cancer.
    Riano I; Abuali I; Sharma A; Durant J; Dragnev KH
    Pharmaceuticals (Basel); 2023 Feb; 16(2):. PubMed ID: 37259381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant immunotherapy in early-stage resectable non-small cell lung cancer: A new milestone.
    Tang WF; Ye HY; Tang X; Su JW; Xu KM; Zhong WZ; Liang Y
    Front Oncol; 2023; 13():1063183. PubMed ID: 36776323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant and Adjuvant Immunotherapy in Resectable NSCLC.
    Bogatsa E; Lazaridis G; Stivanaki C; Timotheadou E
    Cancers (Basel); 2024 Apr; 16(9):. PubMed ID: 38730571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction treatment in patients with stage III non-small cell lung cancer.
    Palmero R; Vilariño N; Navarro-Martín A; Nadal E
    Transl Lung Cancer Res; 2021 Jan; 10(1):539-554. PubMed ID: 33569335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The earlier, the better? A review of neoadjuvant immunotherapy in resectable non-small-cell lung cancer.
    Li F; Chen Y; Wu J; Li C; Chen S; Zhu Z; Qin W; Liu M; Hu B; Liu S; Zhong W
    Chronic Dis Transl Med; 2022 Jun; 8(2):100-111. PubMed ID: 35774424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging biomarkers for neoadjuvant immune checkpoint inhibitors in operable non-small cell lung cancer.
    Pradhan M; Chocry M; Gibbons DL; Sepesi B; Cascone T
    Transl Lung Cancer Res; 2021 Jan; 10(1):590-606. PubMed ID: 33569339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The new era of immune checkpoint inhibition and target therapy in early-stage non-small cell lung cancer. A review of the literature.
    Catania C; Muthusamy B; Spitaleri G; Del Signore E; Pennell NA
    Clin Lung Cancer; 2022 Mar; 23(2):108-115. PubMed ID: 34952792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and Efficacy of Neoadjuvant Immune Checkpoint Inhibitor Therapy in Patients with Resectable Non-small-Cell Lung Cancer: A Systematic Review.
    Zhao Z; Gao Y; Xue Q; Gao S; He J
    Target Oncol; 2021 Jul; 16(4):425-434. PubMed ID: 33983556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.